…at 24 hours (44% vs. 24%) and 48 hours (34% vs. 20%). One-third were pain-free at two hours post-dose with active treatment compared to 17% with placebo. The proportion achieving meaningful pain relief at two hours was 70% with intranasal sumatriptan versus 45% with placebo, according to patient self-rating. Fewer patients on active treatment required rescue medications (37% vs 52%). One patient receiving intranasal sumatriptan reported mild pare…

…r et al. AAN 2015; abstract P2.170). During the observation period, 36.4% of aMCI patients with impaired olfaction developed AD, compared to 17.3% of aMCI patients with intact olfaction. The ROC AUC for conversion to AD was 0.62, which the authors noted is comparable to CSF biomarkers such as beta-amyloid42, tau and p-tau. Thus, impaired olfaction may be an easily administered, low-cost tool for stratifying the risk of conversion from aMCI to AD….